Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C4 | P17516 | 1/20 | 0.56 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.56 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.56 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 4/20 | 0.45 |
| ▸ | HTT | P42858 | 4/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | LMNA | P02545 | 4/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | LCK | P06239 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29683626 | 1.00 | AKR1C4 (0.56) | AKR1C4AKR1C3AKR1C2AKR1C1MEN1 | |
| SCHEMBL8055907 | 0.95 | AKR1C3 (0.51) | AKR1C4AKR1C3AKR1C2AKR1C1MEN1 | |
| SCHEMBL8057769 | 0.85 | AKR1C4 (0.42) | AKR1C4AKR1C3AKR1C2AKR1C1MEN1 | |
| SCHEMBL8055952 | 0.85 | AKR1C4 (0.42) | AKR1C4AKR1C3AKR1C2AKR1C1MEN1 | |
| SCHEMBL11119474 | 0.84 | AKR1C4 (0.47) | AKR1C4AKR1C3AKR1C2AKR1C1MEN1 | |
| SCHEMBL11117678 | 0.81 | HSPD1 (0.48) | AKR1C4AKR1C3AKR1C2AKR1C1MEN1 | |
| SCHEMBL11117667 | 0.81 | NPC1 (0.46) | AKR1C4AKR1C3AKR1C2AKR1C1MEN1 | |
| SCHEMBL8372190 | 0.81 | AKR1C4 (0.55) | AKR1C4AKR1C3AKR1C2AKR1C1MEN1 | |
| SCHEMBL8372186 | 0.81 | AKR1C4 (0.55) | AKR1C4AKR1C3AKR1C2AKR1C1MEN1 | |
| SCHEMBL17627594 | 0.78 | AKR1C4 (0.60) | AKR1C4AKR1C3AKR1C2AKR1C1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090023632-A1 | Hemoglobin-haptoglobin complexes | HEMOSOL, INC. (CA) | 2009-01-22 | — | — | US | claimed |
| US-20030013642-A1 | Hemoglobin-haptoglobin complexes | HEMOSOL, INC. | 2003-01-16 | — | — | US | claimed |
| EP-0669940-B1 | SPECIFICALLY CROSSLINKED HEMOGLOBIN WITH FREE FUNCTIONALITY | UNIV TORONTO (CA) | 1999-02-10 | — | — | EP | claimed |
| US-5399671-A | Specifically crosslinked hemoglobin with free functionality | UNIVERSITY OF TORONTO INNOVATIONS FOUNDATION, THE (CA) | 1995-03-21 | — | — | US | claimed |
| US-11793787-B2 | Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis | THE BROAD INSTITUTE, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11576978-B2 | Hemoglobin-based therapeutic agents | Cheer Global Limited (CN) | 2023-02-14 | — | — | US | disclosed |
| US-11298407-B2 | Hemoglobin based oxygen carrier and method of preparation | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2022-04-12 | — | — | US | disclosed |
| US-20210015935-A1 | HEMOGLOBIN-BASED THERAPEUTIC AGENTS | Cheer Global Limited (HK) | 2021-01-21 | — | — | US | disclosed |
| WO-2018053634-A1 | HEMOGLOBIN BASED OXYGEN CARRIER AND METHOD OF PREPARATION | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2018-03-29 | — | — | WO | disclosed |
| US-20120213732-A1 | TARGETED DELIVERY OF ANTIVIRAL COMPOUNDS THROUGH HEMOGLOBIN BIOCONJUGATES | THERAPURE BIOPHARMA INC. (CA) | 2012-08-23 | — | — | US | disclosed |
| US-20090023632-A1 | Hemoglobin-haptoglobin complexes | HEMOSOL, INC. (CA) | 2009-01-22 | — | — | US | disclosed |
| US-20070060535-A1 | Targeted delivery of antiviral compounds through hemoglobin bioconjugates | THERAPURE BIOPHARMA INC. (CA) | 2007-03-15 | — | — | US | disclosed |
| EP-0785920-A1 | MULTIFUNCTIONAL CROSS-LINKING REAGENTS FOR HEMOGLOBIN, AND CROSS-LINKED HEMOGLOBIN CONJUGATES | KLUGER, Ronald (CA) | 1997-07-30 | — | — | EP | disclosed |
| WO-1997000236-A1 | MULTIFUNCTIONAL CROSS-LINKING REAGENTS FOR HEMOGLOBIN, AND CROSS-LINKED HEMOGLOBIN CONJUGATES | KLUGER RONALD (CA) | 1997-01-03 | — | — | WO | disclosed |
| EP-0669940-A1 | SPECIFICALLY CROSSLINKED HEMOGLOBIN WITH FREE FUNCTIONALITY | THE UNIVERSITY OF TORONTO INNOVATIONS FOUNDATION (CA) | 1995-09-06 | — | — | EP | disclosed |
| EP-0669940-A1 | SPECIFICALLY CROSSLINKED HEMOGLOBIN WITH FREE FUNCTIONALITY | THE UNIVERSITY OF TORONTO INNOVATIONS FOUNDATION (CA) | 1995-09-06 | — | — | EP | disclosed |
| US-5399671-A | Specifically crosslinked hemoglobin with free functionality | UNIVERSITY OF TORONTO INNOVATIONS FOUNDATION, THE (CA) | 1995-03-21 | — | — | US | disclosed |
| US-5399671-A | Specifically crosslinked hemoglobin with free functionality | UNIVERSITY OF TORONTO INNOVATIONS FOUNDATION, THE (CA) | 1995-03-21 | — | — | US | disclosed |
| WO-1994011399-A1 | SPECIFICALLY CROSSLINKED HEMOGLOBIN WITH FREE FUNCTIONALITY | KLUGER RONALD (CA) | 1994-05-26 | — | — | WO | disclosed |
| WO-1994011399-A1 | SPECIFICALLY CROSSLINKED HEMOGLOBIN WITH FREE FUNCTIONALITY | KLUGER RONALD (CA) | 1994-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120213732-A1 | TARGETED DELIVERY OF ANTIVIRAL COMPOUNDS THROUGH HEMOGLOBIN BIOCONJUGATES | HAVCR2, FCGR3B, CD68 | AKR1C4 906/4885AKR1C3 385/4885AKR1C2 1142/4885 |
| US-20070060535-A1 | Targeted delivery of antiviral compounds through hemoglobin bioconjugates | HAVCR2, FCGR3B, CD68 | AKR1C4 906/4885AKR1C3 385/4885AKR1C2 1142/4885 |
| US-20210015935-A1 | HEMOGLOBIN-BASED THERAPEUTIC AGENTS | HBG1, HBG2, HBB | AKR1C4 3538/4885AKR1C3 3817/4885AKR1C2 3251/4885 |
| US-11576978-B2 | Hemoglobin-based therapeutic agents | HBG1, HBG2, HBB | AKR1C4 3538/4885AKR1C3 3817/4885AKR1C2 3251/4885 |
| US-11298407-B2 | Hemoglobin based oxygen carrier and method of preparation | HBZ, HBB, HBG2 | AKR1C4 703/4885AKR1C3 867/4885AKR1C2 651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.